Major Chinese Pharmaceutical Companies Announce Key Developments and Product Updates on March 14 Evening

　　【Pharmaceutical Network Industry DynamicsOn the evening of March 14, a large number of listed pharmaceutical companies on the Shanghai and Shenzhen stock exchanges released important announcements, including China Meheco, Yixintang, and Winning Health Technology, among others. The author has compiled a brief summary of the news.
 

　　[Testing Related]
 

Yirui Biotech: Antigen detection products have not yet obtained a medical device registration certificate in China
 

Yirui Biotech Announces that the Antigen Detection Products of the Company and Its Wholly-Owned Subsidiary, Xiupu Biotech, Have Not Yet Obtained a Medical Device Registration Certificate Issued by China's Drug Supervision and Administration Department. Additionally, Shareholder Sequoia Zhisheng Plans to Reduce Its Stake by No More Than 16,034,400 Shares (4% of the Company’s Total Equity); Directors and General Manager Lu Hehua and Director Fu Hui Plan to Jointly Reduce Their Holdings by No More Than 1.69%.
 

Vazyme: The impact of antigen test kits on the company's performance cannot be specifically predicted yet
 

Novozymes Releases Announcement on Abnormal Stock Trading Fluctuations: Its wholly-owned subsidiary, Novozymes Medical, has recently obtained the "Medical Device Registration Certificate" issued by the National Medical Products Administration for its newly produced antigen test kit. The registration covers changes in the intended use of the medical device product, addition of sample types, and updates to the instructions. The sales of the aforementioned products are subject to various factors and may face the risk of intense market competition. The continuous impact on the company's future performance cannot be specifically predicted at this time.
 

　　[Drug Progress]
 

Growthell: GST-HG141 Phase Ib Clinical Trial Yields Positive Results
 

Gloria Pharmaceuticals announced that its innovative hepatitis B treatment drug GST-HG141 has completed Phase Ib clinical trials. The study results showed that GST-HG141 demonstrated good safety, pharmacodynamics, and pharmacokinetic characteristics in Chinese patients with chronic hepatitis B. The Phase Ib clinical trial achieved positive results, supporting the continuation of GST-HG141 into Phase II clinical trials.
 

China Meheco: PAXLOVID-related business has no significant impact on the company's recent operating performance
 

China Meheco Announcement: On March 9, 2022, the company signed an agreement with Pfizer, Inc. to be responsible for the commercial operation of Pfizer's PAXLOVID in the Chinese market during the term of the agreement (2022). This product is a prescription drug and has not yet been included in the national medical insurance or China’s diagnosis and treatment plans. Its usage and sales performance remain highly uncertain. Moreover, the scale of related business is expected to account for a small proportion of the company's overall business volume, and will not have a significant impact on the company's recent operating results.
 

Changjiang Health: No Cooperation with Shionogi on COVID-19 Treatment Drugs
 

Changjiang Health announced in the evening that the company has noticed recent market rumors about its cooperation with Shionogi & Co., Ltd. regarding COVID-19 treatment drugs. The company clarified: Currently, the company has reached a cooperation with Chang'ao Pharmaceutical Technology Group Co., Ltd., a subsidiary of Shionogi, on “Luliconazole Cream” (brand name: Lulit). To date, no cooperation on COVID-19 treatment drugs has been carried out between the two parties.
 

　　【Share Repurchase】
 

Winning Health: Plans to Repurchase Shares for No Less Than 100 Million Yuan
 

Winning Health Announcement: The company plans to use its own funds to repurchase company shares through centralized bidding. The total amount of the proposed repurchase is no less than 100 million yuan and no more than 1.5 billion yuan, with a repurchase price not exceeding 15 yuan per share. The repurchased shares are intended for future implementation of employee stock ownership plans, equity incentives, or for conversion into convertible corporate bonds issued by the listed company.
 

　　【Performance Express】
 

Yixintang: Net profit increased by 16.65% year-on-year in 2021
 

Yixintang Releases 2021 Annual Earnings Flash Report: Revenue Totals 14.585 Billion Yuan, Up 15.24% Year-on-Year; Net Profit Attributable to Shareholders Reaches 921 Million Yuan, Up 16.65% Year-on-Year; Basic Earnings Per Share at 1.56 Yuan. In 2021, the company's businesses developed steadily. As of December 31, 2021, the company operated a total of 8,560 directly-run chain stores, with a net increase of 1,355 stores throughout the year.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.